CLONOSEQ

clonoSEQ provides more than a binary (yes/no) assessment of the presence of disease.[1] The assay quantifies residual disease, tracks the identified sequences over time, and monitors for the emergence of new sequences, which may signal disease evolution or recurrence. The deep sensitivity of the clonoSEQ Assay has been shown to help predict patient outcomes and add insight to the evaluation of disease response to therapy, enabling timely decisions about how and when to intervene... clonoSEQ leverages the power of next-generation DNA sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.

Also known as: Adaptive Biotechnologies